Abstract:This study aims to develop an in vitro barrier effect test over biomimetic membrane, which is useful to establish the film forming ability of a substance-based medical device (SB-MD). The method contemplates a multiparametric approach including: i ) the measurement of the transmembrane passage of a molecular-like marker over a lipid-impregnated biomimetic membrane (simulating the skin and gastro-intestinal and buccal tissues) by using a static diffusion cell apparatus (Franz cell); and ii ) the evaluation of the integrity of the membrane (colorimetric test). In the first step, a series of lipid-impregnated biomimetic membranes (simulating gastro-intestinal, buccal, and skin tissues) were implemented and their permeability performance validated using model drugs (caffeine and acyclovir) by referring to literature data. As a result, the apparent permeability (P app ) of caffeine over the biomimetic gastro-intestinal membrane (P app = 30.5E-6 cm/s) was roughly comparable to the literature values obtained with Caco-2 cell line membrane (P app = 30.8E-6 cm/s) and with the Franz cell method (P app = 36.2E-6 cm/s). Acyclovir was shown to be a poorly permeable substance both in the literature and experimental data. Following this step, the permeability study was extended to both biomimetic buccal and skin (STRAT-M ® ) membranes: for caffeine, biomimetic gastro-intestinal membrane was the most permeable (P app = 30.5E-6 cm/s), followed by the buccal (P app = 18.2E-6 cm/s) then the skin (P app = 0.5E-6 cm/s) biomimetic membranes. In a second part of the work, the barrier effect test was developed following a similar permeability-like approach. The protocol was designed with the idea of assessing the capacity of a certain product to prevent the passage of caffeine across the biomimetic membrane with respect to a negative and positive control. The untreated membrane was the negative control, while membrane covered with a Vaseline film was the positive. As a last step, the developed barrier effect protocol was applied to an experimental gel-like SB-MD under development for the treatment of aphthae (Aphthae gel, an invented trade name), herein used as a case study. Regarding the results, Aphthae gel reduced the caffeine passage by 60.3%, thus highlighting its effectiveness to form a protective film. Overall, these results provide important knowledge and may pave the way for the use—including for industrial applications—of these simple but effective biomimetic membranes for carrying out high throughput screening necessary to design safe and effective SB-MDs before proceeding further with clinical trials, as requested by the regulations.

Permeapad™ for investigation of passive drug permeability: The effect of surfactants, co-solvents and simulated intestinal fluids (FaSSIF and FeSSIF)

New biomimetic barrier PermeapadTM for efficient investigation of passive permeability of drugs

Determination of Apparent Drug Permeability Coefficients Through Chitosan-Sodium Cellulose Sulfate Polyelectrolyte Complex Films

Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs

Drug Permeability Profiling Using the Novel Permeapad® 96-Well Plate

Safety and efficacy of substance-based medical devices: Design of an in vitro barrier effect test

Validation of an Ex Vivo Permeation Method for the Intestinal Permeability of Different BCS Drugs and Its Correlation with Caco-2 In Vitro Experiments

Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs

High-Throughput SFC-MS/MS Method to Measure EPSA and Predict Human Permeability

Interpreting permeability as a function of free drug fraction: The case studies of cyclodextrins and liposomes

Paracellular Pathway Enhancement of Metformin Hydrochloride via Molecular Dispersion in Span 60 Microparticles

Kinetics of lipid bilayer permeation of a series of ionisable drugs and their correlation with human transporter-independent intestinal permeability

Biorelevant media for transport experiments in the Caco-2 model to evaluate drug absorption in the fasted and the fed state and their usefulness

Interactions of oral permeation enhancers with lipid membranes in simulated intestinal environments

Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers

Simultaneous Lc-Ms/Ms Determination of Danshensu and Paeoniflorin for Permeability Studies in Caco-2 Intestinal Absorption Model

Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media

Optimization of a Parallel Artificial Membrane Permeability Assay for the Fast and Simultaneous Prediction of Human Intestinal Absorption and Plasma Protein Binding of Drug Candidates: Application to Dibenz[b,f]azepine-5-Carboxamide Derivatives

Human intestinal fluid factors affecting intestinal drug permeation in vitro

Parafilm® M and Strat-M® as skin simulants in in vitro permeation of dissolving microarray patches loaded with proteins

TIRF Microscopy‐Based Monitoring of Drug Permeation Across a Lipid Membrane Supported on Mesoporous Silica